JP2023508893A - Whepドメイン融合による目的タンパク質の水溶性増進方法 - Google Patents
Whepドメイン融合による目的タンパク質の水溶性増進方法 Download PDFInfo
- Publication number
- JP2023508893A JP2023508893A JP2022537446A JP2022537446A JP2023508893A JP 2023508893 A JP2023508893 A JP 2023508893A JP 2022537446 A JP2022537446 A JP 2022537446A JP 2022537446 A JP2022537446 A JP 2022537446A JP 2023508893 A JP2023508893 A JP 2023508893A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- eprs
- trs
- peptide
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 88
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 10
- 230000004927 fusion Effects 0.000 title description 11
- 238000000034 method Methods 0.000 title description 7
- 241000588724 Escherichia coli Species 0.000 claims abstract description 48
- 102100026126 Proline-tRNA ligase Human genes 0.000 claims abstract description 42
- 101100535994 Caenorhabditis elegans tars-1 gene Proteins 0.000 claims abstract description 14
- 239000013604 expression vector Substances 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 101710154606 Hemagglutinin Proteins 0.000 claims description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 4
- 101710176177 Protein A56 Proteins 0.000 claims description 4
- 108010092115 glutamyl-prolyl-tRNA synthetase Proteins 0.000 claims description 4
- 239000000185 hemagglutinin Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 101000630284 Homo sapiens Proline-tRNA ligase Proteins 0.000 abstract description 38
- 102000037865 fusion proteins Human genes 0.000 abstract description 18
- 108020001507 fusion proteins Proteins 0.000 abstract description 18
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 239000005090 green fluorescent protein Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 18
- 239000006166 lysate Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 17
- 239000004365 Protease Substances 0.000 description 17
- 108090000467 Interferon-beta Proteins 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 102000003996 Interferon-beta Human genes 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229960001388 interferon-beta Drugs 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000723792 Tobacco etch virus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 108010076818 TEV protease Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101150075071 TRS1 gene Proteins 0.000 description 2
- 101710182223 Toxin B Proteins 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 108010027375 bacterioferritin Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 108010092041 Lysine-tRNA Ligase Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- 244000004005 Nypa fruticans Species 0.000 description 1
- 235000005305 Nypa fruticans Nutrition 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000003614 protease activity assay Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01015—Proline--tRNA ligase (6.1.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01017—Glutamate-tRNA ligase (6.1.1.17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/18011—Comoviridae
- C12N2770/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190171057 | 2019-12-19 | ||
KR10-2019-0171057 | 2019-12-19 | ||
PCT/KR2020/018837 WO2021125917A1 (fr) | 2019-12-19 | 2020-12-21 | Procédé pour l'amélioration de la solubilité dans l'eau d'une protéine cible par fusion du domaine whep |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023508893A true JP2023508893A (ja) | 2023-03-06 |
Family
ID=76478452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022537446A Pending JP2023508893A (ja) | 2019-12-19 | 2020-12-21 | Whepドメイン融合による目的タンパク質の水溶性増進方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230041904A1 (fr) |
EP (1) | EP4079845A1 (fr) |
JP (1) | JP2023508893A (fr) |
KR (1) | KR20210079235A (fr) |
CN (1) | CN114829590A (fr) |
WO (1) | WO2021125917A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2800281C (fr) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Decouverte innovante de compositions therapeutiques, diagnostiques, et d'anticorps associes a des fragments de proteine de lysyl-tarn synthetases |
KR101908438B1 (ko) * | 2016-02-05 | 2018-10-16 | (주)피앤피바이오팜 | Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물 |
KR101914779B1 (ko) * | 2016-03-18 | 2018-11-02 | (주)인테라 | 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터 |
KR102014826B1 (ko) * | 2017-11-23 | 2019-08-28 | (주)인테라 | 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질 |
KR102038876B1 (ko) * | 2018-04-24 | 2019-11-01 | (주)인테라 | 목적 단백질의 수용성 발현을 증진시키기 위한 신규한 펩타이드 |
-
2020
- 2020-12-21 CN CN202080088097.XA patent/CN114829590A/zh active Pending
- 2020-12-21 WO PCT/KR2020/018837 patent/WO2021125917A1/fr unknown
- 2020-12-21 EP EP20903722.5A patent/EP4079845A1/fr active Pending
- 2020-12-21 US US17/787,277 patent/US20230041904A1/en active Pending
- 2020-12-21 KR KR1020200180321A patent/KR20210079235A/ko not_active Application Discontinuation
- 2020-12-21 JP JP2022537446A patent/JP2023508893A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210079235A (ko) | 2021-06-29 |
WO2021125917A1 (fr) | 2021-06-24 |
CN114829590A (zh) | 2022-07-29 |
EP4079845A1 (fr) | 2022-10-26 |
US20230041904A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guerrero et al. | Tandem SUMO fusion vectors for improving soluble protein expression and purification | |
Sheng et al. | Agrobacterium-plant cell DNA transport: have virulence proteins, will travel. | |
CN101351550B (zh) | 具有卓越的伴侣和折叠活性的嵌合融合蛋白 | |
JP5823483B2 (ja) | 塩基性タンパク質タグに融合したプロセシング酵素 | |
US20070248536A1 (en) | Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography | |
JP2015226547A (ja) | 融合タンパク質の自己タンパク質分解切断による組換えタンパク質の産生 | |
KR19980025768A (ko) | 수용성 단백질을 생산하는 새로운 발현 플라스미드 | |
JP2005514025A (ja) | タンパク質発現及び精製のための方法及び組成 | |
JP2008509682A (ja) | Yebfを利用するタンパク質の製造方法 | |
Ruan et al. | Conversion of the molecular chaperone Spy into a novel fusion tag to enhance recombinant protein expression | |
JP2014512814A (ja) | 大腸菌での異種タンパク質生成のための新規発現および分泌ベクター系 | |
WO2006078273A2 (fr) | Procedes et compositions permettant de produire des proteines recombinees | |
KR101373297B1 (ko) | 대장균 포스포글리세르산 인산화효소 유전자를 융합 파트너로서 포함하는 발현벡터 | |
US20160122793A1 (en) | Fusion Protease | |
CA3087218C (fr) | Synthese biologique de chaines d'acides amines pour la preparation de peptides et de proteines | |
JP5865002B2 (ja) | 組換えプラスミドベクターおよびそれを用いたタンパク質の製造方法 | |
AU777246B2 (en) | Microbial protein expression system | |
JP2023508893A (ja) | Whepドメイン融合による目的タンパク質の水溶性増進方法 | |
JP2023551047A (ja) | ウイルス様粒子及びそれらの製造方法 | |
KR102000490B1 (ko) | 가용성이 개선된 살모넬라균 편모 유래 플라젤린 단백질 발현 형질전환체, 그 제조방법 및 용도 | |
US20190300586A1 (en) | Artificial forisome bodies with seo-f fusion proteins, plant or yeast cells with vectors for encoding these proteins and vectors for encoding seo-f fusion proteins | |
JPWO2004031243A1 (ja) | タンパク質ポリマー及びその製造方法 | |
Vijayakumar | Controlled Design and Production of Tunable Modular Protein Nanoparticles | |
KR101658082B1 (ko) | Eda를 융합파트너로 이용한 재조합 단백질의 제조방법 | |
CN116355934A (zh) | mRNA加帽酶及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240305 |